In both mouse and human tumor models, the TCF1+PD-1+ CD8+ T cell subset exhibited high proliferative potential, a better efficacy in controlling tumors, and superior therapeutic effects combined with a PD-1 blockade compared to the TCF1- subset18. Here, CD8A is linked to neoplasm.